Regulatory approval for new antihumoral therapies: Addressing the barriers

American Journal of Transplantation

Volumn 11, Issue 5, 2011, Pages 880-881

  Woodle, E S ^a   Gebel, H M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

antibody mediated rejection; histology; HLA antibodies

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ANTIBODY MEDIATED REJECTION; CLINICAL PROTOCOL; DESENSITIZATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION;

EID: 79955528333     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03526.x     Document Type: Editorial

References (5)

1. Archdeacon P, Chan M, Neuland C, et al,. Summary of FDA antibody mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
2. Guidance for the use of Bayesian statistics in medical device clinical trials. Available at:. Accessed March 24, 2011.
3. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
4. Burns JM, Cornell LD, Perry DK, et al,. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
5. Everly MJ, Everly JJ, Arend LJ, et al,. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.